Design, Synthesis, and Biological Evaluation of New 8-Trifluoromethylquinoline Containing Pyrazole-3-carboxamide Derivatives
No Thumbnail Available
Date
2017
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
HeteroCorporation
Abstract
The article describes the design, synthesis, and characterization of a new series of 8-trifluoromethylquinoline substituted pyrazole-3-carboxamides (9a, 9b, 9c, 9d, 9e, 9f, 9g, 9h, 9i, 9j, 9k, 9l, 9m, 9n, 9o, 9p, 9q, 9r, 9s, 9t) derived from different primary and secondary amines. The intermediate and target compounds were characterized using spectroscopic methods. The structures of intermediate 7 and target molecule 9d were evidenced by the single crystal X-ray study. All the synthesized target compounds (9a, 9b, 9c, 9d, 9e, 9f, 9g, 9h, 9i, 9j, 9k, 9l, 9m, 9n, 9o, 9p, 9q, 9r, 9s, 9t) and three intermediates (6, 7, 8) were screened for their in vitro antitubercular activity against Mycobacterium tuberculosis H<inf>37</inf>Rv strain. Two compounds, 9k and 9t, showed significant inhibition activity with MIC of 3.13 µg/mL, which is comparable with the activity of standard drug, ethambutol. The carboxamides derived from benzylamine derivatives were more active than their aniline analogs. In general, the hybrid amides with a N-methylene linkage (-CONHCH<inf>2</inf>-) exhibited enhanced antitubercular activity. In the antibacterial screening, intermediate 3-hydrazinyl-2-methyl-8-(trifluoromethyl)quinoline (6) displayed remarkable activity against the tested bacterial strains. Further, the active anti-TB derivatives were non-toxic to benign NIH 3T3 cells, which demonstrate the lack of general cellular toxicity and hence signifies their suitability for further lead development. © 2015 HeteroCorporation
Description
Keywords
(2,6 dimethylmorpholino)[1 [2 methyl 8 (trifluoromethyl)quinolin 4 yl] 5 (pyridin 3 yl) 1h pyrazol 3 yl]methanone, 1 [2 methyl 8 (trifluoromethyl) 4 quinolyl] 5 (3 pyridyl) n [[4 (trifluoromethoxy)phenyl]methyl]pyrazole 3 carboxamide, 1 [2 methyl 8 (trifluoromethyl) 4 quinolyl] 5 (3 pyridyl) n [[4 (trifluoromethyl)phenyl]methyl]pyrazole 3 carboxamide, 1 [2 methyl 8 (trifluoromethyl) 4 quinolyl] n (4 tolylmethyl) 5 (3 pyridyl)pyrazole 3 carboxamide, 1 [2 methyl 8 (trifluoromethyl)quinolin 4 yl] 5 (pyridin 3 yl) n (2,2,2 trifluoroethyl) 1h pyrazole 3 carboxamide, 1 [2 methyl 8 (trifluoromethyl)quinolin 4 yl] 5 (pyridin 3 yl) n 3 tolyl 1h pyrazole 3 carboxamide, 1 [2 methyl 8 (trifluoromethyl)quinolin 4 yl] 5 (pyridin 3 yl) n 4 tolyl 1h pyrazole 3 carboxamide, 1 [2 methyl 8 (trifluoromethyl)quinolin 4 yl] 5 (pyridin 3 yl) n [3 (trifluoromethyl)phenyl] 1h pyrazole 3 carboxamide, 1 [2 methyl 8 (trifluoromethyl)quinolin 4 yl] 5 (pyridin 3 yl) n [4 (trifluoromethoxy)phenyl] 1h pyrazole 3 carboxamide, 1 [2 methyl 8 (trifluoromethyl)quinolin 4 yl] 5 (pyridin 3 yl) n [4 (trifluoromethyl)phenyl] 1h pyrazole 3 carboxamide, amide, antibiotic agent, ciprofloxacin, ethambutol, isoniazid, n (4 fluorophenyl) 1 [2 methyl 8 (trifluoromethyl)quinolin 4 yl] 5 (pyridin 3 yl) 1h pyrazole 3 carboxamide, n (4 methoxyphenyl) 1 [2 methyl 8 (trifluoromethyl)quinolin 4 yl] 5 (pyridin 3 yl) 1h pyrazole 3 carboxamide, n (cyclopropylmethyl) 1 [2 methyl 8 (trifluoromethyl)quinolin 4 yl] 5 (pyridin 3 yl) 1h pyrazole 3 carboxamide, n cyclopropyl 1 [2 methyl 8 (trifluoromethyl)quinolin 4 yl] 5 (pyridin 3 yl) 1h pyrazole 3 carboxamide, n tert butyl 1 [2 methyl 8 (trifluoromethyl)quinolin 4 yl] 5 (pyridin 3 yl) 1h pyrazole 3 carboxamide, n [(4 fluorophenyl)methyl] 1 [2 methyl 8 (trifluoromethyl) 4 quinolyl] 5 (3 pyridyl)pyrazole 3 carboxamide, n [(4 methoxyphenyl)methyl] 1 [2 methyl 8 (trifluoromethyl) 4 quinolyl] 5 (3 pyridyl)pyrazole 3 carboxamide, pyrazinamide, pyrazole derivative, quinoline derivative, tuberculostatic agent, unclassified drug, [1 [2 methyl 8 (trifluoromethyl)quinolin 4 yl] 5 (pyridin 3 yl) 1h pyrazol 3 yl](4 methyl piperidin 1 yl)methanone, [1 [2 methyl 8 (trifluoromethyl)quinolin 4 yl] 5 (pyridin 3 yl) 1h pyrazol 3 yl](morpholino)methanone, [1 [2 methyl 8 (trifluoromethyl)quinolin 4 yl] 5 (pyridin 3 yl) 1h pyrazol 3 yl](piperidin 1 yl)methanone, 3T3 cell line, antibacterial activity, Article, bacterial growth, bacterial strain, comparative study, controlled study, drug cytotoxicity, drug design, drug screening, drug structure, drug synthesis, Escherichia coli, in vitro study, minimum inhibitory concentration, Mycobacterium tuberculosis, nonhuman, Pseudomonas aeruginosa, Staphylococcus aureus, X ray crystallography
Citation
Journal of Heterocyclic Chemistry, 2017, 54, 1, pp. 171-182
